These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 18418400)
1. The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade. Kelley-Hedgepeth A; Peter I; Kip K; Montefusco M; Kogan S; Cox D; Ordovas J; Levy D; Reis S; Mendelsohn M; Housman D; Huggins G J Hum Hypertens; 2008 Jul; 22(7):512-5. PubMed ID: 18418400 [TBL] [Abstract][Full Text] [Related]
2. Protective effect of the KCNMB1 E65K genetic polymorphism against diastolic hypertension in aging women and its relevance to cardiovascular risk. Sentí M; Fernández-Fernández JM; Tomás M; Vázquez E; Elosua R; Marrugat J; Valverde MA Circ Res; 2005 Dec; 97(12):1360-5. PubMed ID: 16293791 [TBL] [Abstract][Full Text] [Related]
3. The KCNMB1 E65K variant is associated with reduced central pulse pressure in the community-based Framingham Offspring Cohort. Kelley-Hedgepeth A; Peter I; Montefusco MC; Levy D; Benjamin EJ; Vasan RS; Mendelsohn ME; Housman D; Huggins GS; Mitchell GF J Hypertens; 2009 Jan; 27(1):55-60. PubMed ID: 19050450 [TBL] [Abstract][Full Text] [Related]
4. The KCNMB1 Glu65Lys polymorphism associates with reduced systolic and diastolic blood pressure in the Inter99 study of 5729 Danes. Nielsen T; Burgdorf KS; Grarup N; Borch-Johnsen K; Hansen T; Jørgensen T; Pedersen O; Andersen G J Hypertens; 2008 Nov; 26(11):2142-6. PubMed ID: 18854753 [TBL] [Abstract][Full Text] [Related]
5. The dominant models of KCNJ11 E23K and KCNMB1 E65K are associated with essential hypertension (EH) in Asian: Evidence from a meta-analysis. Zhancheng W; Wenhui J; Yun J; Lingli W; Huijun H; Yan S; Jin L Medicine (Baltimore); 2019 Jun; 98(23):e15828. PubMed ID: 31169684 [TBL] [Abstract][Full Text] [Related]
6. Common charge-shift mutation Glu65Lys in K+ channel β₁-Subunit KCNMB1: pleiotropic consequences for glomerular filtration rate and progressive renal disease. Chen Y; Salem RM; Rao F; Fung MM; Bhatnagar V; Pandey B; Mahata M; Waalen J; Nievergelt CM; Lipkowitz MS; Hamilton BA; Mahata SK; O'Connor DT Am J Nephrol; 2010; 32(5):414-24. PubMed ID: 20861615 [TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphism discovery and haplotype analysis of Ca2+-dependent K+ channel beta-1 subunit. Gong Y; Beitelshees AL; Wessel J; Langaee TY; Schork NJ; Johnson JA Pharmacogenet Genomics; 2007 Apr; 17(4):267-75. PubMed ID: 17496725 [TBL] [Abstract][Full Text] [Related]
8. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Beitelshees AL; Gong Y; Wang D; Schork NJ; Cooper-Dehoff RM; Langaee TY; Shriver MD; Sadee W; Knot HJ; Pepine CJ; Johnson JA; Pharmacogenet Genomics; 2007 Sep; 17(9):719-29. PubMed ID: 17700361 [TBL] [Abstract][Full Text] [Related]
9. Sluggish genes and hypertension. Jordan J J Hypertens; 2008 Nov; 26(11):2093-5. PubMed ID: 18854745 [No Abstract] [Full Text] [Related]
10. Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Filigheddu F; Reid JE; Troffa C; PinnaParpaglia P; Argiolas G; Testa A; Skolnick M; Glorioso N Pharmacogenomics J; 2004; 4(3):154-60. PubMed ID: 15069461 [No Abstract] [Full Text] [Related]
11. beta2-adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. Jia H; Sharma P; Hopper R; Dickerson C; Lloyd DD; Brown MJ J Hypertens; 2000 Jun; 18(6):687-93. PubMed ID: 10872552 [TBL] [Abstract][Full Text] [Related]
12. Hypertension of Kcnmb1-/- is linked to deficient K secretion and aldosteronism. Grimm PR; Irsik DL; Settles DC; Holtzclaw JD; Sansom SC Proc Natl Acad Sci U S A; 2009 Jul; 106(28):11800-5. PubMed ID: 19556540 [TBL] [Abstract][Full Text] [Related]
13. E65 K polymorphism in KCNMB1 gene is not associated with ischaemic heart disease in Spanish patients. Via M; Valveny N; López-Alomar A; Athanasiadis G; Pintó X; Domingo E; Esteban E; González-Pérez E; Moral P J Hum Genet; 2005; 50(11):604-606. PubMed ID: 16155733 [TBL] [Abstract][Full Text] [Related]
14. The future of pharmacogenetics in the treatment of hypertension. Cunningham PN; Chapman AB Pharmacogenomics; 2019 Feb; 20(3):129-132. PubMed ID: 30808251 [No Abstract] [Full Text] [Related]
15. Single-nucleotide polymorphisms in vascular Ca2+-activated K+-channel genes and cardiovascular disease. Köhler R Pflugers Arch; 2010 Jul; 460(2):343-51. PubMed ID: 20043229 [TBL] [Abstract][Full Text] [Related]
16. Genetic variation in the KCNMA1 potassium channel alpha subunit as risk factor for severe essential hypertension and myocardial infarction. Tomás M; Vázquez E; Fernández-Fernández JM; Subirana I; Plata C; Heras M; Vila J; Marrugat J; Valverde MA; Sentí M J Hypertens; 2008 Nov; 26(11):2147-53. PubMed ID: 18854754 [TBL] [Abstract][Full Text] [Related]
17. The smooth muscle cell-restricted KCNMB1 ion channel subunit is a direct transcriptional target of serum response factor and myocardin. Long X; Tharp DL; Georger MA; Slivano OJ; Lee MY; Wamhoff BR; Bowles DK; Miano JM J Biol Chem; 2009 Nov; 284(48):33671-82. PubMed ID: 19801679 [TBL] [Abstract][Full Text] [Related]